The loss of Ligand Pharmaceuticals under GAAP for 9 months of 2020 amounted to $8.746 million, against a profit of $636.667 million in the previous year. Revenue increased by 24.8% to $116.429 million compared to $93.279 million a year earlier.
The loss of Ligand Pharmaceuticals under GAAP for 9 months of 2020 amounted to $8.746 million, against a profit of $636.667 million in the previous year. Revenue increased by 24.8% to $116.429 million compared to $93.279 million a year earlier. 
investor.ligand.com
English (US) 